STOCK TITAN

Harrow Health to Participate in H.C. Wainwright Global Life Sciences Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Harrow Health, Inc. (NASDAQ: HROW) announced participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. CEO Mark Baum and CFO Andrew Boll will engage in a virtual presentation available on the company's investor relations site starting March 9, 2021, at 7:00 a.m. ET, archived for 90 days. The management team will also hold one-on-one meetings via H.C. Wainwright. Harrow Health specializes in ophthalmic healthcare and owns ImprimisRx, a leader in ophthalmology outsourcing and pharmaceutical compounding.

Positive
  • None.
Negative
  • None.

NASHVILLE, Tenn., March 02, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the H.C. Wainwright Global Life Sciences Conference to be held virtually on March 9-10, 2021.

Harrow Health’s pre-recorded presentation will be available via a link on the investor relations section of its website, harrowinc.com, beginning at 7:00 a.m. ET on Tuesday, March 9, 2021, and will remain archived there for approximately 90 days. Harrow Health’s management team will be participating in one-on-one meetings during the conference. Interested investors can request meetings exclusively via H. C. Wainwright.

About Harrow Health
Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns ImprimisRx, the nation’s leading ophthalmology outsourcing and pharmaceutical compounding business, which was founded in 2014. Harrow Health also holds large equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries. Harrow Health also owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com.

Contact:
Jamie Webb
Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737


FAQ

What is Harrow Health's participation in the H.C. Wainwright Global Life Sciences Conference?

Harrow Health, Inc. (HROW) will participate in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

When will Harrow Health's presentation be available for viewing?

The pre-recorded presentation will be available starting March 9, 2021, at 7:00 a.m. ET.

How long will Harrow Health's presentation be archived?

The presentation will be archived for approximately 90 days.

Who from Harrow Health will be presenting at the conference?

CEO Mark Baum and CFO Andrew Boll will be participating in the conference.

How can investors request a one-on-one meeting with Harrow Health's management?

Investors can request meetings exclusively through H.C. Wainwright.

Harrow, Inc.

NASDAQ:HROW

HROW Rankings

HROW Latest News

HROW Stock Data

1.53B
30.59M
14.11%
59.27%
7.28%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
NASHVILLE